Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir

Peter Lischka; Douglas Zhang; Daniel Holder; Holger Zimmermann

doi:10.1016/j.antiviral.2016.06.008

Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir

Peter Lischka, Douglas Zhang, Daniel Holder, Holger Zimmermann

Biostatistics

Research output: Contribution to journal › Article › peer-review

16 Citations (SciVal)

Abstract

Letermovir is a novel anti-HCMV drug in Phase III development that targets the UL56 subunit of the viral terminase complex. In immunocompromised patients four major glycoprotein B (gB) subtypes are known and may influence pathogenesis and thus disease outcomes. Using a panel of 74 letermovir-naïve, low-passage, clinical HCMV isolates, we examined the potential impact of i) gB genotype and ii) naturally occurring UL56 sequence variations upon susceptibility to letermovir. Our data show that letermovir's potency is independent of gB subtype and show that naturally-occurring letermovir-resistance is rare or possibly absent.

Original language	English
Pages (from-to)	204-209
Number of pages	6
Journal	Antiviral Research
Volume	132
DOIs	https://doi.org/10.1016/j.antiviral.2016.06.008
State	Published - Aug 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier B.V.

ASJC Scopus subject areas

Pharmacology
Virology

Access to Document

10.1016/j.antiviral.2016.06.008

Cite this

@article{63f9ac53272a47259a6f7e0d2d35e028,

title = "Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir",

abstract = "Letermovir is a novel anti-HCMV drug in Phase III development that targets the UL56 subunit of the viral terminase complex. In immunocompromised patients four major glycoprotein B (gB) subtypes are known and may influence pathogenesis and thus disease outcomes. Using a panel of 74 letermovir-na{\"i}ve, low-passage, clinical HCMV isolates, we examined the potential impact of i) gB genotype and ii) naturally occurring UL56 sequence variations upon susceptibility to letermovir. Our data show that letermovir's potency is independent of gB subtype and show that naturally-occurring letermovir-resistance is rare or possibly absent.",

author = "Peter Lischka and Douglas Zhang and Daniel Holder and Holger Zimmermann",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier B.V.",

year = "2016",

month = aug,

day = "1",

doi = "10.1016/j.antiviral.2016.06.008",

language = "English",

volume = "132",

pages = "204--209",

}

TY - JOUR

T1 - Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir

AU - Lischka, Peter

AU - Zhang, Douglas

AU - Holder, Daniel

AU - Zimmermann, Holger

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Letermovir is a novel anti-HCMV drug in Phase III development that targets the UL56 subunit of the viral terminase complex. In immunocompromised patients four major glycoprotein B (gB) subtypes are known and may influence pathogenesis and thus disease outcomes. Using a panel of 74 letermovir-naïve, low-passage, clinical HCMV isolates, we examined the potential impact of i) gB genotype and ii) naturally occurring UL56 sequence variations upon susceptibility to letermovir. Our data show that letermovir's potency is independent of gB subtype and show that naturally-occurring letermovir-resistance is rare or possibly absent.

AB - Letermovir is a novel anti-HCMV drug in Phase III development that targets the UL56 subunit of the viral terminase complex. In immunocompromised patients four major glycoprotein B (gB) subtypes are known and may influence pathogenesis and thus disease outcomes. Using a panel of 74 letermovir-naïve, low-passage, clinical HCMV isolates, we examined the potential impact of i) gB genotype and ii) naturally occurring UL56 sequence variations upon susceptibility to letermovir. Our data show that letermovir's potency is independent of gB subtype and show that naturally-occurring letermovir-resistance is rare or possibly absent.

UR - http://www.scopus.com/inward/record.url?scp=84977178224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977178224&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2016.06.008

DO - 10.1016/j.antiviral.2016.06.008

M3 - Article

C2 - 27345658

AN - SCOPUS:84977178224

SN - 0166-3542

VL - 132

SP - 204

EP - 209

JO - Antiviral Research

JF - Antiviral Research

ER -

Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this